Technical Analysis for NVCT - Nuvectis Pharma, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| D | 6.41 | -14.19% | -1.06 |
NVCT closed down 14.19 percent on Friday, November 1, 2024, on 1.74 times normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline. The stock fell below its 200 day moving average, damaging its long-term outlook by crossing under that critical trendline.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Fell Below 20 DMA | Bearish | 0.00% | |
| Fell Below 200 DMA | Bearish | 0.00% | |
| Fell Below 50 DMA | Bearish | 0.00% | |
| MACD Bearish Signal Line Cross | Bearish | 0.00% | |
| New Downtrend | Bearish | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| 20 DMA Support | Bullish | -14.19% | |
| 200 DMA Support | Bullish | -14.19% | |
| Wide Bands | Range Expansion | -14.19% | |
| Calm After Storm | Range Contraction | -18.76% |
| Alert | Time |
|---|---|
| 50 DMA Support | about 19 hours ago |
| Down 5% | about 19 hours ago |
| Down 1 ATR | about 19 hours ago |
| Down 3% | about 22 hours ago |
| Fell Below 200 DMA | about 22 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 08/07/2024
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of targeted small molecule therapeutics for the treatment of cancer. The company develops NXP800, an oral small molecule inhibitor of the Heat Shock Factor 1 pathway, a signaling pathway in the initiation and progression of various cancers; and NXP900 program, an oral small molecule designed to inhibit the SRC and YES1 kinases. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Life Sciences Biology Treatment Of Cancer Tyrosine Kinase Oncogenes Cancer Research Small Molecule Kinase Proto Oncogene Tyrosine Protein Kinase Src
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Life Sciences Biology Treatment Of Cancer Tyrosine Kinase Oncogenes Cancer Research Small Molecule Kinase Proto Oncogene Tyrosine Protein Kinase Src
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 12.1 |
| 52 Week Low | 5.85 |
| Average Volume | 117,920 |
| 200-Day Moving Average | 7.16 |
| 50-Day Moving Average | 6.80 |
| 20-Day Moving Average | 7.20 |
| 10-Day Moving Average | 7.93 |
| Average True Range | 0.66 |
| RSI (14) | 39.39 |
| ADX | 26.87 |
| +DI | 20.35 |
| -DI | 27.73 |
| Chandelier Exit (Long, 3 ATRs) | 7.09 |
| Chandelier Exit (Short, 3 ATRs) | 7.88 |
| Upper Bollinger Bands | 9.03 |
| Lower Bollinger Band | 5.36 |
| Percent B (%b) | 0.29 |
| BandWidth | 51.13 |
| MACD Line | 0.28 |
| MACD Signal Line | 0.36 |
| MACD Histogram | -0.0793 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 8.22 | ||||
| Resistance 3 (R3) | 8.42 | 8.02 | 7.92 | ||
| Resistance 2 (R2) | 8.02 | 7.56 | 7.92 | 7.82 | |
| Resistance 1 (R1) | 7.21 | 7.27 | 7.01 | 7.01 | 7.72 |
| Pivot Point | 6.81 | 6.81 | 6.71 | 6.71 | 6.81 |
| Support 1 (S1) | 6.01 | 6.35 | 5.81 | 5.81 | 5.10 |
| Support 2 (S2) | 5.61 | 6.07 | 5.51 | 5.00 | |
| Support 3 (S3) | 4.80 | 5.61 | 4.90 | ||
| Support 4 (S4) | 4.60 |
